INSERM, Laboratory of Integrative Cancer Immunology, Paris, France.
Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Oncoimmunology. 2023 Aug 5;12(1):2243169. doi: 10.1080/2162402X.2023.2243169. eCollection 2023.
In the last decade, a plethora of immunotherapeutic strategies have been designed to modulate the tumor immune microenvironment. In particular, immune checkpoint (IC) blockade therapies present the most promising advances made in cancer treatment in recent years. In non-small cell lung cancer (NSCLC), biomarkers predicting response to IC treatments are currently lacking. We have recently identified Immunoscore-IC, a powerful biomarker that predicts the efficiency of immune-checkpoint inhibitors (ICIs) in NSCLC patients. Immunoscore-IC is an in vitro diagnostic assay that quantifies densities of PD-L1+, CD8+ cells, and distances between CD8+ and PD-L1+ cells in the tumor microenvironment. Immunoscore-IC can classify responder non-responder NSCLC patients for ICIs therapy and is revealed as a promising predictive marker of response to anti-PD-1/PD-L1 immunotherapy in these patients. Immunoscore-IC has also shown a significant predictive value, superior to the currently used PD-L1 marker. In colorectal cancer (CRC), the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab improved progression-free survival (PFS) in patients with previously untreated metastatic CRC. In the AtezoTRIBE trial, Immunoscore-IC emerged as the first biomarker with robust predictive value in stratifying pMMR metastatic CRC patients who critically benefit from checkpoint inhibitors. Thus, Immunoscore-IC could be a universal biomarker to predict response to PD-1/PD-L1 checkpoint inhibitor immunotherapy across multiple cancer indications. Therefore, cancer patient stratification (by Immunoscore-IC), based on the presence of T lymphocytes and PD-L1 potentially provides support for clinicians to guide them through combination cancer treatment decisions.
在过去的十年中，已经设计了大量的免疫治疗策略来调节肿瘤免疫微环境。特别是，免疫检查点（IC）阻断疗法是近年来癌症治疗中最有前途的进展。在非小细胞肺癌（NSCLC）中，目前缺乏预测对 IC 治疗反应的生物标志物。我们最近确定了 Immunoscore-IC，这是一种强大的生物标志物，可预测 NSCLC 患者免疫检查点抑制剂（ICI）的疗效。Immunoscore-IC 是一种体外诊断检测方法，可定量肿瘤微环境中 PD-L1+、CD8+细胞的密度以及 CD8+和 PD-L1+细胞之间的距离。Immunoscore-IC 可以将 ICI 治疗的 responder 和 non-responder NSCLC 患者进行分类，并被揭示为这些患者对抗 PD-1/PD-L1 免疫治疗反应的有前途的预测标志物。Immunoscore-IC 还显示出显著的预测价值，优于目前使用的 PD-L1 标志物。在结直肠癌（CRC）中，在一线 FOLFOXIRI 加贝伐珠单抗的基础上加用 atezolizumab 可改善未经治疗的转移性 CRC 患者的无进展生存期（PFS）。在 AtezoTRIBE 试验中，Immunoscore-IC 成为第一个具有稳健预测价值的生物标志物，可分层 pMMR 转移性 CRC 患者，这些患者从检查点抑制剂中获益关键。因此，Immunoscore-IC 可能成为预测 PD-1/PD-L1 检查点抑制剂免疫治疗在多种癌症适应证中反应的通用生物标志物。因此，基于 T 淋巴细胞和 PD-L1 的存在对癌症患者进行分层（通过 Immunoscore-IC），可能为临床医生提供支持，以指导他们做出联合癌症治疗决策。
